The Record - Issue 18: Autumn 2020

57 in a safe and efficient manner,” says Ruosi. “To achieve this goal, our team undergoes training that has been specifically designed for pharmaceutical and biotech manufacturers. This means we fully understand the opera- tional and regulatory challenges the industry faces, as well as the integral role our solution plays in ensuring patient safety.” Built as a commercial-off-the-shelf solu- tion on the Microsoft Dynamics 365 platform, AX for Pharma 365 is the world’s only ERP system with integrated modules that are preconfigured specifically for the biotech, pharmaceutical and life sciences industries. It enables organisations to handle everything from everything from the supply chains for clinical trials to weighing and dispensing, manufacturing execution, advanced quality management, warehouse management, logistics, financial planning and much more. “Our solution empowers pharmaceutical and biotech companies to run clinical trials for Covid-19 vaccines and drugs, while also ensur- ing they have the agility, flexibility and scalability to manage the manufacturing and distribution processes once their products are approved,” says Ruosi. “Crucially, AX for Pharma 365 has been extensively tested and validated for standard use in the pharmaceutical and biotech industries, so it guarantees compliance with all necessary regu- lations, such as Good Automated Manufacturing Practice, Good Manufacturing Practice, and US Food and Drug Administration 21 CFR Part 11.” Pharmaceutical and biotech companies from around the world have already adopted AX for Pharma 365 to manage their R&D projects and clinical trials for Covid-19, as well as many other illnesses and diseases. For example, one multinational pharmaceu- tical company has selected the solution to run hundreds of clinical trials for Covid-19 around the world. Similarly, a biotech and medical device company is using it to support all their clinical and commercial processes. Meanwhile, a central European group comprising of more than 20 companies chose AX for Pharma 365 to manage its R&D projects for finding a drug to counteract the neurological impact of Covid-19. Another European pharmaceutical manufacturer relies on the solution to manufacture all its commercial drugs (more than 200 products), including some that can help to treat patients with Covid-19. “These companies are at the forefront of the fight against Covid-19, and many other illnesses and diseases, and by implementing our end- to-end solution, they have automated all their processes and made themmore accurate and effi- cient, transformed their supply chains and saved thousands of dollars per year,” says Ruosi. “Now they have the flexibility and agility they need to quickly respond to changing healthcare needs, which may enable them to pursue R&D projects and clinical trials that were not financially feasible in the past. This may lead to the development of innovative new drugs, devices and therapies that will help patients live healthier and safer lives. We’re proud to be part of that journey.” “Public cloud and AI technologies are provid- ing pharma and medtech corporations with the robustness, flexibility and scalability they need for the research and development of new mole- cules and gathering of real-life clinical evidence for production and distribution,” says Bruno Denys, the business lead for pharma and chem- ical industries at Microsoft. “AX for Pharma’s years of in-depth expertise of pharmaceutical process automation combined with Microsoft’s powerful technology, plus a strong service partnership, ensures the success of pharma and medtech clients’ digital transformation projects. In healthcare, trust is key. This is at the heart of AX for Pharma and Microsoft’s approach.”